This inventor holds 4 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: Adamed Pharma S.a., Adamed Sp. Z O.o.. Active years: 2014-2025.
Company Filing History:
Years Active: 2014-2025
Title: Marcin Kolaczkowski: Innovator in Pharmaceutical Chemistry
Introduction
Marcin Kolaczkowski is a notable inventor based in Wieliczka, Poland. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for the treatment of various neurological disorders. With a total of 4 patents to his name, Kolaczkowski's work is paving the way for advancements in medical treatments.
Latest Patents
Kolaczkowski's latest patents include innovative compounds such as indole and benzimidazole derivatives that act as dual 5-HT and 5-HT receptor antagonists. These compounds are represented by a specific formula and are designed to prevent and treat diseases like Alzheimer's disease, Parkinson's disease, Lewy body dementia, and various psychotic conditions. Another significant patent involves indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists, which also target similar neurological disorders and mental health issues.
Career Highlights
Throughout his career, Marcin Kolaczkowski has worked with prominent companies in the pharmaceutical industry, including Adamed Pharma S.A. and Adamed Sp. z o.o. His experience in these organizations has allowed him to collaborate on groundbreaking research and development projects that focus on improving patient outcomes through innovative drug therapies.
Collaborations
Some of Kolaczkowski's notable coworkers include Adam Bucki and Monika Marcinkowska. Their collaborative efforts have contributed to the success of various projects and patents in the field of pharmaceutical chemistry.
Conclusion
Marcin Kolaczkowski is a distinguished inventor whose work in pharmaceutical chemistry is making a significant impact on the treatment of neurological disorders. His innovative patents and collaborations highlight his commitment to advancing medical science and improving the quality of life for patients.